Mouse models of acute exacerbations of allergic asthma

Respirology

Volumn 21, Issue 5, 2016, Pages 842-849

  Kumar, Rakesh K ^a   Herbert, Cristan ^a   Foster, Paul S ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

allergic asthma; animal models; exacerbations; preclinical studies; respiratory viruses

Indexed keywords

GALACTOSIDE BINDING LECTIN; INTERLEUKIN 5; LECTIN; OVALBUMIN; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AIR POLLUTION; ALLERGIC ASTHMA; ANIMAL HOUSING; ASPERGILLUS; CONIDIUM; DERMATOPHAGOIDES; DISEASE EXACERBATION; DISEASE MODEL; ENVIRONMENTAL FACTOR; HUMAN RHINOVIRUS; HUMAN RHINOVIRUS 1B; MENGO VIRUS; MOUSE MODEL; NONHUMAN; PNEUMONIA VIRUS OF MICE INFECTION; PNEUMOVIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHINOVIRUS INFECTION;

EID: 84975047112     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12760     Document Type: Review

References (85)

1. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125: 1081–102.
2. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin. Exp. Allergy 2009; 39: 193–202.
3. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59–99.
4. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization consultation on severe asthma. J. Allergy Clin. Immunol. 2010; 126: 926–38.
5. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm. Med. 2009; 9: 24.
6. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 2007; 30: 452–6.
7. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax 2006; 61: 909–15.
8. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J. Allergy Clin. Immunol. 2011; 128: 1165–74.
9. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1995; 151: 879–86.
10. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, Martin AC, Geelhoed GC, McMinn PC, Goldblatt J et al. Association between human rhinovirus C and severity of acute asthma in children. Eur. Respir. J. 2011; 37: 1037–42.
11. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 2010; 125: 1178–87.
12. Weinmayr G, Romeo E, De Sario M, Weiland SK, Forastiere F. Short-term effects of PM10 and NO2 on respiratory health among children with asthma or asthma-like symptoms: a systematic review and meta-analysis. Environ. Health Perspect. 2010; 118: 449–57.
13. Spira-Cohen A, Chen LC, Kendall M, Lall R, Thurston GD. Personal exposures to traffic-related air pollution and acute respiratory health among Bronx schoolchildren with asthma. Environ. Health Perspect. 2011; 119: 559–65.
14. Murray CS, Simpson A, Custovic A. Allergens, viruses, and asthma exacerbations. Proc. Am. Thorac. Soc. 2004; 1: 99–104.
15. Castro M, Bloch SR, Jenkerson MV, DeMartino S, Hamilos DL, Cochran RB, Zhang XE, Wang H, Bradley JP, Schechtman KB et al. Asthma exacerbations after glucocorticoid withdrawal reflects T cell recruitment to the airway. Am. J. Respir. Crit. Care Med. 2004; 169: 842–9.
16. Kumar RK, Jeffery PK. Pathology of asthma. In: Adkinson NF, Bochner BS, Burks W, Busse WW, Holgate ST, Lemanske RF, O'Hehir RE. (eds) Middleton's Allergy, 8th edn. Elsevier, Cambridge, 2013; 986–99.
17. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Jr., Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 2011; 127: 355–60.
18. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18: 716–25.
19. Yan X, Chu JH, Gomez J, Koenigs M, Holm C, He X, Perez MF, Zhao H, Mane S, Martinez FD et al. Non-invasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am. J. Respir. Crit. Care Med. 2015; 191: 1116–25.
20. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J. Allergy Clin. Immunol. 2002; 109: S447–60.
21. de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M, Fontes ES, Fernezlian S, Garippo AL, Castro I, Castro FF, de Arruda Martins M, Saldiva PH et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin. Exp. Allergy 2005; 35: 602–11.
22. Thompson BR, Douglass JA, Ellis MJ, Kelly VJ, O'Hehir RE, King GG, Verbanck S. Peripheral lung function in patients with stable and unstable asthma. J. Allergy Clin. Immunol. 2013; 131: 1322–8.
23. Hohlfeld JM, Ahlf K, Enhorning G, Balke K, Erpenbeck VJ, Petschalles J, Hoymann HG, Fabel H, Krug N. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am. J. Respir. Crit. Care Med. 1999; 159: 1803–9.
24. Dolhnikoff M, da Silva LF, de Araujo BB, Gomes HA, Fernezlian S, Mulder A, Lindeman JH, Mauad T. The outer wall of small airways is a major site of remodeling in fatal asthma. J. Allergy Clin. Immunol. 2009; 123: 1090–7, 7 e1.
25. Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007; 62: 475–82.
26. Rohde G, Message SD, Haas JJ, Kebadze T, Parker H, Laza-Stanca V, Khaitov MR, Kon OM, Stanciu LA, Mallia P et al. CXC-chemokines and antimicrobial peptides in rhinovirus-induced experimental asthma exacerbations. Clin. Exp. Allergy 2014; 44: 930–9.
27. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, O'Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 2007; 176: 988–93.
28. Mercer PF, Abbott-Banner K, Adcock IM, Knowles RG. Translational models of lung disease. Clin. Sci. (Lond.) 2015; 128: 235–56.
29. Kumar RK, Foster PS. Are mouse models of asthma appropriate for investigating the pathogenesis of airway hyper-responsiveness? Front Physiol 2012; 3: 312.
30. Martin RA, Hodgkins SR, Dixon AE, Poynter ME. Aligning mouse models of asthma to human endotypes of disease. Respirology 2014; 19: 823–33.
31. Saglani S, Mathie SA, Gregory LG, Bell MJ, Bush A, Lloyd CM. Pathophysiological features of asthma develop in parallel in house dust mite-exposed neonatal mice. Am. J. Respir. Cell Mol. Biol. 2009; 41: 281–9.
32. Siegle JS, Hansbro N, Herbert C, Rosenberg HF, Domachowske JB, Asquith KL, Foster PS, Kumar RK. Early-life viral infection and allergen exposure interact to induce an asthmatic phenotype in mice. Respir. Res. 2010; 11: 14.
33. Herbert C, Siegle JS, Shadie AM, Nikolaysen S, Garthwaite L, Hansbro NG, Foster PS, Kumar RK. Development of asthmatic inflammation in mice following early-life exposure to ambient environmental particulates and chronic allergen challenge. Dis. Model. Mech. 2013; 6: 479–88.
34. Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur. Respir. J. 2015; 45: 1197–207.
35. Siegle JS, Hansbro N, Herbert C, Yang M, Foster PS, Kumar RK. Airway hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic inflammation. Am. J. Respir. Cell Mol. Biol. 2006; 35: 565–70.
36. Herbert C, Scott MM, Scruton KH, Keogh RP, Yuan KC, Hsu K, Siegle JS, Tedla N, Foster PS, Kumar RK. Alveolar macrophages stimulate enhanced cytokine production by pulmonary CD4+ T-lymphocytes in an exacerbation of murine chronic asthma. Am. J. Pathol. 2010; 177: 1657–64.
37. Mori H, Parker NS, Rodrigues D, Hulland K, Chappell D, Hincks JS, Bright H, Evans SM, Lamb DJ. Differences in respiratory syncytial virus and influenza infection in a house-dust-mite-induced asthma mouse model: consequences for steroid sensitivity. Clin. Sci. (Lond.) 2013; 125: 565–74.
38. Clarke DL, Davis NH, Majithiya JB, Piper SC, Lewis A, Sleeman MA, Corkill DJ, May RD. Development of a mouse model mimicking key aspects of a viral asthma exacerbation. Clin. Sci. (Lond.) 2014; 126: 567–80.
39. Katoh S, Shimizu H, Obase Y, Oomizu S, Niki T, Ikeda M, Mouri K, Kobashi Y, Hirashima M, Oka M. Preventive effect of galectin-9 on double-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced asthma in mice. Exp. Lung Res. 2013; 39: 453–62.
40. Snelgrove RJ, Gregory LG, Peiro T, Akthar S, Campbell GA, Walker SA, Lloyd CM. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J. Allergy Clin. Immunol. 2014; 134: 583–92 e6.
41. North ML, Amatullah H, Khanna N, Urch B, Grasemann H, Silverman F, Scott JA. Augmentation of arginase 1 expression by exposure to air pollution exacerbates the airways hyperresponsiveness in murine models of asthma. Respir. Res. 2011; 12: 19.
42. Penton PC, Wang X, Amatullah H, Cooper J, Godri K, North ML, Khanna N, Scott JA, Chow CW. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. J. Allergy Clin. Immunol. 2013; 131: 512–20 e1-10.
43. Shadie AM, Herbert C, Kumar RK. Ambient particulate matter induces an exacerbation of airway inflammation in experimental asthma: role of interleukin-33. Clin. Exp. Immunol. 2014; 177: 491–9.
44. Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. Respir. Res. 2003; 4: 4.
45. Shapiro SD. Animal models of asthma: Pro: allergic avoidance of animal (model[s]) is not an option. Am. J. Respir. Crit. Care Med. 2006; 174: 1171–3.
46. Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr. Drug Targets 2008; 9: 485–94.
47. Stevenson CS, Birrell MA. Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance. Pharmacol. Ther. 2011; 130: 93–105.
48. Holmes AM, Solari R, Holgate ST. Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov. Today 2011; 16: 659–70.
49. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998; 53: 849–56.
50. Bella J, Rossmann MG. Review: rhinoviruses and their ICAM receptors. J. Struct. Biol. 1999; 128: 69–74.
51. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 2008; 14: 199–204.
52. Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J et al. An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog. 2013; 9: e1003520.
53. Del Vecchio AM, Branigan PJ, Barnathan ES, Flavin SK, Silkoff PE, Turner RB. Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 30: 32–43.
54. Rochlitzer S, Hoymann HG, Muller M, Braun A. No exacerbation but impaired anti-viral mechanisms in a rhinovirus-chronic allergic asthma mouse model. Clin. Sci. (Lond.) 2014; 126: 55–65.
55. Phan JA, Kicic A, Berry LJ, Fernandes LB, Zosky GR, Sly PD, Larcombe AN. Rhinovirus exacerbates house-dust-mite induced lung disease in adult mice. PLoS One 2014; 9: e92163.
56. Nagarkar DR, Bowman ER, Schneider D, Wang Q, Shim J, Zhao Y, Linn MJ, McHenry CL, Gosangi B, Bentley JK et al. Rhinovirus infection of allergen-sensitized and -challenged mice induces eotaxin release from functionally polarized macrophages. J. Immunol. 2010; 185: 2525–35.
57. Kim E, Lee H, Kim HS, Won S, Lee EK, Bang K, Chun YH, Yoon JS, Kim HH, Kim JT et al. The effect of rhinovirus on airway inflammation in a murine asthma model. Korean J Pediatr 2013; 56: 482–9.
58. Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, Carpenter H, Don AS, Morris JC, Zimmermann N et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat. Med. 2013; 19: 232–7.
59. Domachowske JB, Bonville CA, Rosenberg HF. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 2004; 23: S228–S34.
60. Peebles RS, Jr., Sheller JR, Johnson JE, Mitchell DB, Graham BS. Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J. Med. Virol. 1999; 57: 186–92.
61. Barends M, Boelen A, de Rond L, Kwakkel J, Bestebroer T, Dormans J, Neijens H, Kimman T. Influence of respiratory syncytial virus infection on cytokine and inflammatory responses in allergic mice. Clin. Exp. Allergy 2002; 32: 463–71.
62. Ishioka T, Yamada Y, Kimura H, Yoshizumi M, Tsukagoshi H, Kozawa K, Maruyama K, Hayashi Y, Kato M. Elevated macrophage inflammatory protein 1alpha and interleukin-17 production in an experimental asthma model infected with respiratory syncytial virus. Int. Arch. Allergy Immunol. 2013; 161 Suppl 2: 129–37.
63. Bonville CA, Bennett NJ, Koehnlein M, Haines DM, Ellis JA, DelVecchio AM, Rosenberg HF, Domachowske JB. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology 2006; 349: 87–95.
64. Mahmutovic-Persson I, Akbarshahi H, Bartlett NW, Glanville N, Johnston SL, Brandelius A, Uller L. Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma. Allergy 2014; 69: 348–58.
65. Starkhammar M, Kumlien Georen S, Swedin L, Dahlen SE, Adner M, Cardell LO. Intranasal administration of poly(I:C) and LPS in BALB/c mice induces airway hyperresponsiveness and inflammation via different pathways. PLoS One 2012; 7: e32110.
66. Starkhammar M, Larsson O, Kumlien Georen S, Leino M, Dahlen SE, Adner M, Cardell LO. Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation. PLoS One 2014; 9: e104114.
67. Fukushima C, Matsuse H, Fukahori S, Tsuchida T, Kawano T, Senjyu H, Kohno S. Aspergillus fumigatus synergistically enhances mite-induced allergic airway inflammation. Med. Sci. Monit. 2010; 16: BR197–202.
68. McGee MA, Kamal AS, McGee JK, Wood CE, Dye JA, Krantz QT, Landis MS, Gilmour MI, Gavett SH. Differential effects of particulate matter upwind and downwind of an urban freeway in an allergic mouse model. Environ. Sci. Technol. 2015; 49: 3930–9.
69. Kierstein S, Krytska K, Sharma S, Amrani Y, Salmon M, Panettieri RA, Jr., Zangrilli J, Haczku A. Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen-sensitized mice. Allergy 2008; 63: 438–46.
70. Kim J, Natarajan S, Vaickus LJ, Bouchard JC, Beal D, Cruikshank WW, Remick DG. Diesel exhaust particulates exacerbate asthma-like inflammation by increasing CXC chemokines. Am. J. Pathol. 2011; 179: 2730–9.
71. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol. Sci. 2010; 31: 335–43.
72. Herbert C, Shadie AM, Bunting MM, Tedla N, Garthwaite L, Freeman A, Yoo H, Park SH, Kumar RK. Anti-inflammatory and anti-remodelling effects of ISU201, a modified form of the extracellular domain of human BST2, in experimental models of asthma: association with inhibition of histone acetylation. PLoS One 2014; 9: e90436.
73. Khaitov MR, Shilovskiy IP, Nikonova AA, Shershakova NN, Kamyshnikov OY, Babakhin AA, Zverev VV, Johnston SL, Khaitov RM. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 2014; 25: 642–50.
74. Bunting MM, Shadie AM, Flesher RP, Nikiforova V, Garthwaite L, Tedla N, Herbert C, Kumar RK. Interleukin-33 drives activation of alveolar macrophages and airway inflammation in a mouse model of acute exacerbation of chronic asthma. Biomed. Res. Int. 2013; 2013: 250938.
75. Flesher RP, Herbert C, Kumar RK. Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma. Clin. Sci. (Lond.) 2014; 126: 805–14.
76. Hiroshima Y, Garthwaite L, Hsu K, Yoo H, Park SH, Geczy CL, Kumar RK, Herbert C. ISU201 enhances the resolution of airway inflammation in a mouse model of an acute exacerbation of asthma. Mediators Inflamm. 2015; 2015: 405629.
77. Rasmussen AL, Racaniello VR. Selection of rhinovirus 1A variants adapted for growth in mouse lung epithelial cells. Virology 2011; 420: 82–8.
78. Rosenthal LA, Szakaly RJ, Amineva SP, Xing Y, Hill MR, Palmenberg AC, Gern JE, Sorkness RL. Lower respiratory tract infection induced by a genetically modified picornavirus in its natural murine host. PLoS One 2012; 7: e32061.
79. Ito K, Herbert C, Siegle JS, Vuppusetty C, Hansbro N, Thomas PS, Foster PS, Barnes PJ, Kumar RK. Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. Am. J. Respir. Cell Mol. Biol. 2008; 39: 543–50.
80. Ohmoto Y, Wood MJ, Charlton HM, Kajiwara K, Perry VH, Wood KJ. Variation in the immune response to adenoviral vectors in the brain: influence of mouse strain, environmental conditions and priming. Gene Ther. 1999; 6: 471–81.
81. Booth JL, Umstead TM, Hu S, Dybvig KF, Cooper TK, Wilson RP, Chroneos ZC. Housing conditions modulate the severity of Mycoplasma pulmonis infection in mice deficient in class A scavenger receptor. Comp. Med. 2014; 64: 424–39.
82. Yun Y, Srinivas G, Kuenzel S, Linnenbrink M, Alnahas S, Bruce KD, Steinhoff U, Baines JF, Schaible UE. Environmentally determined differences in the murine lung microbiota and their relation to alveolar architecture. PLoS One 2014; 9: e113466.
83. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–8.
84. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189–97.
85. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1198–207.